Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

IHMT-TRK-284 shows efficacy in models of TRK kinase fusion or mutant-driven cancers

Jan. 7, 2021

The Vanderbilt University synthesizes new compounds for cancer

Jan. 7, 2021

Wistar Institute patents ACSS2 inhibitors

Jan. 7, 2021

CANTATA study of telaglenastat in renal cell carcinoma misses primary endpoint

Jan. 5, 2021

Ryvu submits CTA to begin phase I/II trial of RVU-120 in solid tumors

Jan. 5, 2021

BET inhibitor ODM-207 is safe in fist-in-human study in patients with solid tumors

Jan. 5, 2021

Ryvu Therapeutics identifies hSTING receptor agonists

Jan. 5, 2021

Ayala plans pivotal phase II/III RINGSIDE study of AL-102 in desmoid tumors

Jan. 5, 2021

Vivoryon Therapeutics patents meprin A inhibitors

Jan. 5, 2021

University of Alberta discovers ERCC1 inhibitors

Jan. 4, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...